Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus

Lupus

Volumn 21, Issue 3, 2012, Pages 279-287

  Lertnawapan, R ^a   Bian, A ^a   Rho, Y H ^a   Raggi, P ^b   Oeser, A ^a   Solus, J F ^a   Gebretsadik, T ^a   Shintani, A ^a   Stein, C M ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

atherosclerosis; cystatin C; inflammation; renal function; systemic lupus erythematosus

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; CREATININE; CYSTATIN C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FRAMINGHAM RISK SCORE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODIFIED DIET IN RENAL DISEASE ESTIMATED GLOMERULUS FILTRATION RATE; PRIORITY JOURNAL; RACE; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD SEDIMENTATION; CALCIUM; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; KIDNEY DISEASES; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 84856755373     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311425527     Document Type: Article

References (43)

1. Bokenkamp A, Herget-Rosenthal S, Bokenkamp R. Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol. 2006 ; 21: 1223-1230 (Pubitemid 44203445)
2. Chew JS, Saleem M, Florkowski CM, Goerge PM. Cystatin C-a paradigm of evidence based laboratory medicine. Clin Biochem Rev. 2008 ; 29: 47-62
3. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 2006 ; 70: 1403-1412 (Pubitemid 44527309)
4. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005 ; 352: 2049-2060 (Pubitemid 40664306)
5. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006 ; 145: 237-246 (Pubitemid 46768607)
6. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med. 2008 ; 121: 50-57
7. Parikh NI, Hwang SJ, Yang Q, et al. Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol. 2008 ; 102: 1194-1198
8. Bruce IN. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005 ; 44: 1492-1502 (Pubitemid 41742464)
9. Asanuma Y, Oeser An , Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2407-2415 (Pubitemid 37542989)
10. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality; a pooled analysis of community-based studies. J Am Soc Nephrol. 2004 ; 15: 1307-1315 (Pubitemid 38526012)
11. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999 ; 56: 2214-2219 (Pubitemid 30004750)
12. Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus. 2006 ; 15: 562-569 (Pubitemid 44661742)
13. Rho YH, Chung CP, Oeser A, et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol. 2008 ; 35: 1789-1794
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
16. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 ; 39: 363-369 (Pubitemid 26085211)
17. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003 ; 139: 137-147
18. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990 ; 15: 827-832 (Pubitemid 20101575)
19. Agresti A Categorical data analysis. 2 nd edn. New Jersey: John Wiley & Sons, 2002. New Jersey: John Wiley & Sons ; 2002 :
20. Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika. 1967 ; 54: 167-179
21. Sjowall C, Zickert A, Skogh T, Wettero J, Gunnarsson I. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther. 2009 ; 11: R188 - R188
22. Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F. Serum cystatin reliably detects renal dysfunction in patients with various renal diseases. Nephron. 2002 ; 91: 13-20 (Pubitemid 34522827)
23. Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 2011 ; 20: 588-597
24. Lertnawapan R, Bian A, Rho YH, et al. Cystatin C, renal function and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2011 ;:
25. Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol. 2008 ; 9: 9-9
26. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant. 2007 ; 22: 1087-1092 (Pubitemid 46523422)
27. Keller CR, Odden MC, Fried LF, et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int. 2007 ; 71: 239-244 (Pubitemid 46160924)
28. Shlipak MG, Katz R, Cushman M, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005 ; 118: 1416-1416
29. Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010 ; 59: 241-246
30. Backlund A, Holmdahl M, Mattsson R, et al. Cystatin C influences the autoimmune but not inflammatory response to cartilage type II collagen leading to chronic arthritis development. Arthritis Res Ther. 2011 ; 13: R54 - R54
31. Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006 ; 17: 254-261
32. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009 ; 55: 1932-1943
33. Kilic T, Oner G, Ural E, et al. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis. 2009 ; 207: 552-558
34. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005 ; 51: 321-327 (Pubitemid 40175801)
35. Jernberg T, Lindahl B, James S, Larsson A, Hasson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004 ; 110: 2342-2348 (Pubitemid 39407337)
36. Maahs DM, Ogden LG, Kretowski A, et al. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes. 2007 ; 56: 2774-2779 (Pubitemid 350044921)
37. Madero M, Sarnak MJ. Association of cystatin C with adverse outcomes. Curr Opin Nephrol Hypertens. 2009 ; 18: 258-263
38. Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005 ; 45: 268-271 (Pubitemid 40094736)
39. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 ; 352: 1296-1305
40. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002 ; 61: 1486-1494 (Pubitemid 34304510)
41. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002 ; 62: 1402-1407
42. Wang J, Sim AS, Wang XL, et al. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis. 2008 ; 197: 853-859 (Pubitemid 351417885)
43. Ix JH, Katz R, Kestenbaum B, et al. Association of mild to moderate kidney dysfunction and coronary calcification. J Am Soc Nephrol. 2008 ; 19: 579-585 (Pubitemid 351355401)